Literature DB >> 1693784

Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer.

H R Maxon1, L E Schroder, S R Thomas, V S Hertzberg, E A Deutsch, H I Scher, R C Samaratunga, K F Libson, C C Williams, J S Moulton.   

Abstract

Rhenium-186(tin) hydroxyethylidene diphosphonate (HEDP) is a new radiopharmaceutical that localizes in areas of osseous metastases in a manner similar to that of standard bone-scanning agents. It also emits beta particles with sufficient energy to be therapeutically useful. A single intravenous injection of about 33 mCi (1,221 MBq) was given to each of 20 elderly patients with advanced skeletal metastases from hormonally resistant prostate cancer. Prompt, significant relief of pain occurred 80% of the time with no significant side effects and only minimal, transient marrow toxicity. Re-186(Sn) HEDP appears to be a useful new agent for the palliation of painful osseous metastases in prostate cancer.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1693784     DOI： 10.1148/radiology.176.1.1693784

Source DB:  PubMed          Journal:  Radiology        ISSN： 0033-8419            Impact factor:   11.105


  22 in total

Review 1.  Nuclear medicine.

Authors:  P J Ell
Journal:  Postgrad Med J       Date:  1992-02       Impact factor: 2.401

Review 2.  Targeted radionuclide therapy for bone metastases.

Authors:  V J Lewington
Journal:  Eur J Nucl Med       Date:  1993-01

Review 3.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

Review 4.  The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer.

Authors:  Jim N Rose; Juanita M Crook
Journal:  Ther Adv Urol       Date:  2015-06

Review 5.  Treatment of Bone Metastasis with Bone-Targeting Radiopharmaceuticals.

Authors:  Joon Young Choi
Journal:  Nucl Med Mol Imaging       Date:  2018-01-12

6.  A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone.

Authors:  J M O'Sullivan; A R Norman; V R McCready; G Flux; F M Buffa; B Johnson; J Coffey; G Cook; J Treleaven; A Horwich; R A Huddart; C C Parker; D P Dearnaley
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-30       Impact factor: 9.236

7.  Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases.

Authors:  W Y Lin; C P Lin; S J Yeh; B T Hsieh; Z T Tsai; G Ting; T C Yen; S J Wang; F F Knapp; M G Stabin
Journal:  Eur J Nucl Med       Date:  1997-06

8.  Radioimmunoscintigraphy of colorectal cancer with technetium-99m-labeled murine anti-carcinoembryonic antigen monoclonal antibody in athymic nude mice.

Authors:  N Watanabe; N Oriuchi; S Sugiyama; M Kuroki; Y Matsuoka
Journal:  Ann Nucl Med       Date:  1994-02       Impact factor: 2.668

Review 9.  186Re-HEDP for metastatic bone pain in breast cancer patients.

Authors:  Marnix G E H Lam; John M H de Klerk; Peter P van Rijk
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-29       Impact factor: 9.236

10.  Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride.

Authors:  Massimiliano Pacilio; Guido Ventroni; Giuseppe De Vincentis; Bartolomeo Cassano; Rosanna Pellegrini; Elisabetta Di Castro; Viviana Frantellizzi; Giulia Anna Follacchio; Tatiana Garkavaya; Leda Lorenzon; Pasquale Ialongo; Roberto Pani; Lucio Mango
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-13       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.